Compare NEXA & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXA | DFTX |
|---|---|---|
| Founded | 1956 | N/A |
| Country | Luxembourg | United States |
| Employees | 5612 | N/A |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2017 | N/A |
| Metric | NEXA | DFTX |
|---|---|---|
| Price | $14.42 | $22.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $10.40 | ★ $38.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.69 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $14.62 |
| 52 Week High | $16.75 | $26.25 |
| Indicator | NEXA | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 60.63 |
| Support Level | $10.72 | $16.37 |
| Resistance Level | $14.84 | N/A |
| Average True Range (ATR) | 1.06 | 1.39 |
| MACD | 0.25 | 0.04 |
| Stochastic Oscillator | 62.50 | 40.92 |
Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).